Movement Alert｜Iovance Biotherapeutics, Inc. Intraday Decline 25.59%, gains reverse after mNSCLC data webcast

Market Focus10-29

On October 29, Iovance Biotherapeutics, Inc. fell 25.59% in Regular Trading, trading at $11.485 per share, with turnover of $162 million.

The clearest catalyst in the public information is a sharp reversal after the company’s webcast on positive TIL therapy data in metastatic non-small cell lung cancer and its broader precision medicine strategy, following earlier gains in post-market, overnight, and pre-market trading.

Background context shows the company had recently raised full-year revenue guidance to $410 million-$420 million from $350 million-$370 million on strong Amtagvi and Proleukin demand, while consensus expects November 5 quarterly revenue of about $116 million, up 59.56% year over year, and adjusted EPS of negative $0.09. Even so, the latest session move was described as profit-taking after prior optimism had already been priced in.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment